Recent work (Krafft et al., Cell 2013) has demonstrated that amyloid beta oligomers are the synaptotoxic entity at the earliest stages of Alzheimer’s Disease. Acelot has identified novel brain-penetrant small molecule antagonists of synaptotoxic amyloid oligomer action. Acelot has identified several families of potential oligomer antagonists via the JPS…
Read More
It is widely held that soluble Aβ oligomers are the most neurotoxic form of Aβ and that a compromised Aβ clearance rate in the brain may be one cause for late-onset Alzheimer’s disease. Key proteins that mediate Aβ clearance, are ApoE and the ABCA1 lipid transporter. Recent studies from…
Read MoreAt the core of Acelot’s technology is a novel and unique computer algorithm, “JPS”, that has been developed at the University of California and was validated in a variety of studies. JPS allows the identification of latent pharmacophore information and can be used for rapid lead identification and optimization even for drug development projects without clear target information or crystallography data. Furthermore, JPS is useful for screening against undesired pathways and targets to minimize the risk of side-effects.
Acelot has been awarded a prestigious SBIR Grant from the National Institutes of Health for the discovery of novel LXR-based leads for Alzheimer’s disease based on Acelot’s computer-based JPS…
Read More
U.S. patent 9,218,460 on the JPS method has been granted with Ambuj Singh as one of the inventors. Acelot holds an exclusive license for this patent.
Read MoreAcelot co-authored an article in Bioorganic & Medicinal Chemistry Letters on the use of its unique JPS technology for the discovery of novel LRRK2 inhibitors for the treatment of…
Read MoreAcelot will attend the 2014 BIO International Convention on June 23-26 in San Diego. We are looking forward to meet with you at the BIO Business Forum.
Read More
